Cilostazol: Drug information

For additional information see "Cilostazol: Patient drug information"

For abbreviations, symbols, and age group definitions show table

ALERT: US Boxed Warning

Contraindicated in heart failure patients:

Cilostazol is contraindicated with patients with heart failure of any severity. Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared with placebo in patients with class III to IV heart failure.

Pharmacologic Category

Antiplatelet Agent;
Phosphodiesterase-3 Enzyme Inhibitor;
Vasodilator

Dosing: Adult

Intermittent claudication

Intermittent claudication:

Note: Safe to use in combination with either aspirin or clopidogrel (Ref).

Oral: 100 mg twice daily; discontinue treatment if symptoms are not improved after 3 months of therapy.

Noncardioembolic stroke or transient ischemic attack, secondary prevention

Noncardioembolic stroke or transient ischemic attack, secondary prevention (off-label use): Oral: 100 mg twice daily. Note: Clopidogrel or aspirin/extended release dipyridamole recommended over the use of cilostazol (Ref).

Percutaneous coronary intervention

Percutaneous coronary intervention (following elective stent placement) (off-label use): Oral: 100 mg twice daily in combination with aspirin or clopidogrel. Note: Only recommended in patients with an allergy or intolerance to either aspirin or clopidogrel (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Altered kidney function: Oral:

CrCl >25 mL/minute: No dosage adjustment necessary (Ref).

CrCl ≤25 mL/minute: No dosage adjustment necessary. Use with caution as patients with severe kidney impairment have increased concentrations of an active metabolite (OPC-13213) (Ref).

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m²):

Note: Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal SCr concentrations. Younger patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

Oral: No data. No dosage adjustment necessary (Ref).

Hemodialysis, intermittent (thrice weekly): Unlikely to be significantly removed by dialysis (highly protein bound [95% to 98%]) (Ref):

Oral: No dosage adjustment necessary (Ref). A retrospective trial has reported tolerability with use of 100 mg twice daily in hemodialysis patients (Ref). Use with caution as patients with severe kidney impairment have increased concentrations of an active metabolite (OPC-13213) (Ref).

Peritoneal dialysis: Unlikely to be significantly removed by dialysis (highly protein bound [95% to 98%]) (Ref):

Oral: No dosage adjustment necessary (Ref). Use with caution as patients with severe kidney impairment have increased concentrations of an active metabolite (OPC-13213) (Ref).

CRRT: Oral: No dosage adjustment necessary (Ref). Use with caution as patients with severe kidney impairment have increased concentrations of an active metabolite (OPC-13213) (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral: No dosage adjustment necessary (Ref). Use with caution as patients with severe kidney impairment have increased concentrations of an active metabolite (OPC-13213) (Ref).

Dosing: Liver Impairment: Adult

Mild impairment: No dosage adjustment necessary.

Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.

Dosing: Older Adult

Refer to adult dosing.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Central nervous system: Headache (27% to 34%)

Gastrointestinal: Diarrhea (12% to 19%), abnormal stools (12% to 15%)

Infection: Infection (10% to 14%)

Respiratory: Rhinitis (7% to 12%)

1% to 10%:

Cardiovascular: Palpitations (5% to 10%), peripheral edema (7% to 9%), tachycardia (4%), atrial fibrillation (<2%), atrial flutter (<2%), cardiac arrest (<2%), cardiac failure (<2%), cerebral infarction (<2%), edema (<2%), facial edema (<2%), hypotension (<2%), myocardial infarction (<2%), nodal arrhythmia (<2%), orthostatic hypotension (<2%), supraventricular tachycardia (<2%), syncope (<2%), varicose veins (<2%), ventricular premature contractions (<2%), ventricular tachycardia (<2%)

Central nervous system: Dizziness (9% to 10%), vertigo (3%) , anxiety (<2%), chills (<2%), insomnia (<2%), malaise (<2%), neuralgia (<2%)

Dermatologic: Ecchymoses (<2%), furunculosis (eye: <2%), skin hypertrophy (<2%), urticaria (<2%), xeroderma (<2%)

Endocrine & metabolic: Albuminuria (<2%), diabetes mellitus (<2%), gout (<2%), hyperlipidemia (<2%), hyperuricemia (<2%), increased gamma-glutamyl transferase (<2%)

Gastrointestinal: Nausea (7%), dyspepsia (6%), abdominal pain (4% to 5%), flatulence (3%), anorexia (<2%), cholelithiasis (<2%), colitis (<2%), duodenal ulcer (<2%), duodenitis (<2%), esophageal hemorrhage (<2%), esophagitis (<2%), gastric ulcer (<2%), gastritis (<2%), gastroenteritis (<2%), gingival hemorrhage (<2%), hematemesis (<2%), melena (<2%), peptic ulcer (<2%), periodontal abscess (<2%)

Genitourinary: Cystitis (<2%), pelvic pain (<2%), urinary frequency (<2%), vaginal hemorrhage (<2%), vaginitis (<2%)

Hematologic & oncologic: Anemia (<2%), hemorrhage (<2%), hemorrhage (eye, <2%), iron deficiency anemia (<2%), polycythemia (<2%), purpura (<2%), rectal hemorrhage (<2%), retroperitoneal hemorrhage (<2%)

Hypersensitivity: Tongue edema (<2%)

Neuromuscular & skeletal: Back pain (7%), myalgia (3%), arthralgia (<2%), bursitis (<2%), neck stiffness (<2%), ostealgia (<2%)

Ophthalmic: Amblyopia (<2%), blindness (<2%), conjunctivitis (<2%), diplopia (<2%), retinal hemorrhage (<2%)

Otic: Otalgia (<2%), tinnitus (<2%)

Renal: Increased serum creatinine (<2%)

Respiratory: Pharyngitis (10%), cough (3% to 4%), asthma (<2%), epistaxis (<2%), hemoptysis (<2%), pneumonia (<2%), sinusitis (<2%)

Miscellaneous: Fever (<2%)

Postmarketing and/or case reports: Abnormal hepatic function tests, agranulocytosis, anaphylaxis, angina pectoris, angioedema, aplastic anemia, cerebrovascular accident, cerebral hemorrhage, chest pain, coronary thrombosis (stent), fixed drug eruption, gastrointestinal hemorrhage, granulocytopenia, hematoma (extradural), hematuria, hemorrhagic diathesis, hepatic insufficiency, hot flash, hyperglycemia, hypersensitivity, hypertension, increased blood pressure, increased blood urea nitrogen, interstitial pneumonitis, intracranial hemorrhage, jaundice, left ventricular dysfunction (outflow tract obstruction; in patients with sigmoid-shaped interventricular septum), leukopenia, pain, pancytopenia, pulmonary hemorrhage, pruritus, prolonged QT interval on ECG, skin rash, Stevens-Johnson syndrome, subcutaneous hemorrhage, subdural hematoma, thrombocytopenia, thrombosis, torsades de pointes, vasodilation, vomiting

Contraindications

Hypersensitivity to cilostazol or any component of the formulation; heart failure of any severity.

Warnings/Precautions

Concerns related to adverse effects:

• Cardiovascular effects: May induce tachycardia, palpitation, tachyarrhythmia, and/or hypotension. Left ventricular outflow tract obstruction has been reported in patients with sigmoid shaped interventricular septum; monitor for the development of a new systolic murmur or cardiac symptoms after initiating therapy.

• Hematologic effects: Cases of thrombocytopenia or leukopenia progressing to agranulocytosis, reversible upon discontinuation, have been reported when not immediately discontinued; monitor platelets and white blood cell counts periodically.

Disease-related concerns:

• Hemostatic disorders: Avoid use in patients with active pathological bleeding or hemostatic disorders (has not been studied).

• Cardiovascular disease: [US Boxed Warning]: Cilostazol is contraindicated in patients with heart failure of any severity. Phosphodiesterase inhibitors have caused decreased survival compared with placebo in patients with class III to IV heart failure. Patients with history of ischemic heart disease may be at increased risk for exacerbation of angina pectoris or myocardial infarction.

• Hepatic impairment: Use with caution in patients with moderate to severe hepatic impairment (has not been studied).

• Renal impairment: Use with caution in patients with severe renal impairment.

Other warnings/precautions:

• Elective surgery: Time required to recover adequate platelet function is ~2 days (Hall 2011). Of note, bleeding times were not significantly altered by cilostazol after 3 to 14 days of treatment (Kim 2004; Wilhite 2003).

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Generic: 50 mg, 100 mg

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (Cilostazol Oral)

50 mg (per each): $1.82 - $1.93

100 mg (per each): $1.82

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Oral: Administer 30 minutes before or 2 hours after meals (breakfast and dinner).

Use: Labeled Indications

Intermittent claudication: Reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

Use: Off-Label: Adult

Elective PCI with bare metal or drug eluting stent placement (alternative agent); Secondary prevention of noncardioembolic ischemic stroke or transient ischemic attack (TIA)

Medication Safety Issues

Sound-alike/look-alike issues:

Pletal may be confused with Plendil

Metabolism/Transport Effects

Substrate of CYP1A2 (Minor), CYP2C19 (Major with inhibitors), CYP2C19 (Minor with inducers), CYP2D6 (Minor), CYP3A4 (Major with inhibitors), CYP3A4 (Minor with inducers); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; Inhibits CYP3A4 (Weak), ENT1 and CNT3;

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Abciximab: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Abrocitinib: Agents with Antiplatelet Effects may increase antiplatelet effects of Abrocitinib. Risk X: Avoid

Acalabrutinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

ALPRAZolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of ALPRAZolam. Risk C: Monitor

Anagrelide: May increase adverse/toxic effects of Cilostazol. Risk X: Avoid

Anticoagulants: Cilostazol may increase anticoagulant effects of Anticoagulants. Risk C: Monitor

Antiplatelet Agents (P2Y12 Inhibitors): Agents with Antiplatelet Effects may increase antiplatelet effects of Antiplatelet Agents (P2Y12 Inhibitors). Risk C: Monitor

Caplacizumab: Agents with Antiplatelet Effects may increase adverse/toxic effects of Caplacizumab. Specifically, the risk of bleeding may be increased. Risk C: Monitor

CarBAMazepine: CYP3A4 Inhibitors (Weak) may increase serum concentration of CarBAMazepine. Risk C: Monitor

Cladribine: Inhibitors of Equilibrative Nucleoside (ENT1) and Concentrative Nucleoside (CNT3) Transporters may increase serum concentration of Cladribine. Management: Avoid concomitant use of ENT1 or CNT3 inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration. Risk D: Consider Therapy Modification

Clofazimine: May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor

Collagenase (Systemic): Agents with Antiplatelet Effects may increase adverse/toxic effects of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. Risk C: Monitor

CycloSPORINE (Systemic): CYP3A4 Inhibitors (Weak) may increase serum concentration of CycloSPORINE (Systemic). Risk C: Monitor

CYP2C19 Inhibitors (Moderate): May increase serum concentration of Cilostazol. CYP2C19 Inhibitors (Moderate) may increase active metabolite exposure of Cilostazol. Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving moderate inhibitors of CYP2C19. Monitor clinical response to cilostazol closely. Risk D: Consider Therapy Modification

CYP3A4 Inhibitors (Moderate): May increase serum concentration of Cilostazol. Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors. Risk D: Consider Therapy Modification

CYP3A4 Inhibitors (Strong): May increase serum concentration of Cilostazol. Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with strong CYP3A4 inhibitors. Risk D: Consider Therapy Modification

Dasatinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Deoxycholic Acid: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Dofetilide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Dofetilide. Risk C: Monitor

Esomeprazole: May increase active metabolite exposure of Cilostazol. Esomeprazole may increase serum concentration of Cilostazol. Risk C: Monitor

Finerenone: CYP3A4 Inhibitors (Weak) may increase serum concentration of Finerenone. Risk C: Monitor

Flibanserin: CYP3A4 Inhibitors (Weak) may increase serum concentration of Flibanserin. Risk C: Monitor

Fusidic Acid (Systemic): May increase serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Consider avoiding this combination if possible. If required, monitor patients closely for increased adverse effects of the CYP3A4 substrate. Risk D: Consider Therapy Modification

Glycoprotein IIb/IIIa Inhibitors: Agents with Antiplatelet Effects may increase antiplatelet effects of Glycoprotein IIb/IIIa Inhibitors. Risk C: Monitor

Grapefruit Juice: May increase serum concentration of Cilostazol. Management: Advise patients to avoid grapefruit juice when taking cilostazol. If patients regularly consume grapefruit juice, decrease the dose of cilostazol to 50 mg twice daily. Risk D: Consider Therapy Modification

Herbal Products with Anticoagulant/Antiplatelet Effects: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Ibritumomab Tiuxetan: Agents with Antiplatelet Effects may increase antiplatelet effects of Ibritumomab Tiuxetan. Risk C: Monitor

Ibrutinib: Agents with Antiplatelet Effects may increase adverse/toxic effects of Ibrutinib. Specifically, the risk of bleeding and hemorrhage may be increased. Risk C: Monitor

Inotersen: Agents with Antiplatelet Effects may increase adverse/toxic effects of Inotersen. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Ixabepilone: CYP3A4 Inhibitors (Weak) may increase serum concentration of Ixabepilone. Risk C: Monitor

Lemborexant: CYP3A4 Inhibitors (Weak) may increase serum concentration of Lemborexant. Management: The maximum recommended dosage of lemborexant is 5 mg, no more than once per night, when coadministered with weak CYP3A4 inhibitors. Risk D: Consider Therapy Modification

Limaprost: May increase adverse/toxic effects of Agents with Antiplatelet Effects. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Lomitapide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Lomitapide. Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day. Risk D: Consider Therapy Modification

Midazolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of Midazolam. Risk C: Monitor

Miscellaneous Antiplatelets: Agents with Antiplatelet Effects may increase antiplatelet effects of Miscellaneous Antiplatelets. Risk C: Monitor

NiMODipine: CYP3A4 Inhibitors (Weak) may increase serum concentration of NiMODipine. Risk C: Monitor

Obinutuzumab: Agents with Antiplatelet Effects may increase adverse/toxic effects of Obinutuzumab. Specifically, the risk of bleeding may be increased. Management: Consider avoiding coadministration of obinutuzumab and agents with antiplatelet effects, especially during the first cycle of obinutuzumab therapy. Risk D: Consider Therapy Modification

Omeprazole: May increase serum concentration of Cilostazol. Omeprazole may increase active metabolite exposure of Cilostazol. Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving omeprazole. Monitor clinical response to cilostazol closely. Risk D: Consider Therapy Modification

Pentosan Polysulfate Sodium: Agents with Antiplatelet Effects may increase adverse/toxic effects of Pentosan Polysulfate Sodium. Specifically, the risk of hemorrhage may be increased. Risk C: Monitor

Pimozide: CYP3A4 Inhibitors (Weak) may increase serum concentration of Pimozide. Risk X: Avoid

Pirtobrutinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Riociguat: Cilostazol may increase hypotensive effects of Riociguat. Risk C: Monitor

Selumetinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Simvastatin: CYP3A4 Inhibitors (Weak) may increase serum concentration of Simvastatin. CYP3A4 Inhibitors (Weak) may increase active metabolite exposure of Simvastatin. Risk C: Monitor

Sirolimus (Conventional): CYP3A4 Inhibitors (Weak) may increase serum concentration of Sirolimus (Conventional). Risk C: Monitor

Sirolimus (Protein Bound): CYP3A4 Inhibitors (Weak) may increase serum concentration of Sirolimus (Protein Bound). Management: Reduce the dose of protein bound sirolimus to 56 mg/m² when used concomitantly with a weak CYP3A4 inhibitor. Risk D: Consider Therapy Modification

Tacrolimus (Systemic): CYP3A4 Inhibitors (Weak) may increase serum concentration of Tacrolimus (Systemic). Risk C: Monitor

Thrombolytic Agents: Agents with Antiplatelet Effects may increase adverse/toxic effects of Thrombolytic Agents. Specifically, the risk of bleeding may be increased. Risk C: Monitor

Ticlopidine: May increase serum concentration of Cilostazol. Ticlopidine may increase active metabolite exposure of Cilostazol. Risk C: Monitor

Tipranavir: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Triazolam: CYP3A4 Inhibitors (Weak) may increase serum concentration of Triazolam. Risk C: Monitor

Ubrogepant: CYP3A4 Inhibitors (Weak) may increase serum concentration of Ubrogepant. Management: In patients taking weak CYP3A4 inhibitors, the initial and second dose (given at least 2 hours later if needed) of ubrogepant should be limited to 50 mg. Risk D: Consider Therapy Modification

Vitamin E (Systemic): May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Volanesorsen: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Vonoprazan: May increase serum concentration of Cilostazol. Risk C: Monitor

Zanubrutinib: May increase antiplatelet effects of Agents with Antiplatelet Effects. Risk C: Monitor

Food Interactions

Taking cilostazol with a high-fat meal may increase peak concentration by 90% and increase AUC by 25%. Grapefruit juice may increase serum levels of cilostazol and enhance toxic effects. Management: Administer cilostazol on an empty stomach 30 minutes before or 2 hours after meals. Concurrent ingestion of grapefruit juice may require therapy modification; consult drug interactions database for more detailed information.

Pregnancy Considerations

Adverse events have been observed in animal reproduction studies.

Breastfeeding Considerations

It is not known if cilostazol is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.

Monitoring Parameters

Platelets and WBC counts periodically; monitor for the development of a new systolic murmur or cardiac symptoms.

Mechanism of Action

Cilostazol and its metabolites are inhibitors of phosphodiesterase III. As a result, cyclic AMP is increased leading to reversible inhibition of platelet aggregation, vasodilation, and inhibition of vascular smooth muscle cell proliferation.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Effect on walking distance: 2 to 4 weeks; may require up to 12 weeks

Protein binding: Cilostazol 95% to 98%; active metabolites: 66% to 97%

Metabolism: Hepatic; CYP1A2 (minor), CYP2C19 (major), CYP2D6 (minor), CYP3A4 (major).

Half-life elimination: ~11 to 13 hours

Excretion: Urine (74%) and feces (20%) as metabolites

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Severe renal impairment increases active metabolite concentrations and alters protein binding of the parent drug.

Cigarette smoking: Exposure is decreased by ~20% in smokers.

Brand Names: International

International Brand Names by Country

For country code abbreviations (show table)

(AE) United Arab Emirates: Pletal | Pletoz;
(AR) Argentina: Aclusin | Cibrogan | Cilaal | Cilospaw | Cilostal | Cilostane | Cilostazol richet | Cilovas | Citalexon | Corionil | Dencilox | Licuagen | Novamas | Pletaal | Policor | Trastocir | Trombonot | Vasativ xr | Zolplat;
(AU) Australia: Pletal;
(BD) Bangladesh: Cilosta | Claudinil | Inclaud | Vasocil | Zocil;
(BG) Bulgaria: Cilostazol sandoz | Cilostazol stada | Lostrazin | Trombye;
(BR) Brazil: Cebralat | Claudic | Vasativ | Vasogard;
(CL) Chile: Artesol | Cilosvitae | Clauter | Ilostal | Kostal;
(CN) China: BANG PING | Pletaal | Si te li pu | Xi luo;
(CO) Colombia: Angiovan | Aritan | Cilostal | Cilosvitae | Cirvenzol | Licuagen | Ligamax | Praxocol | Sadoxol;
(CZ) Czech Republic: Cilostazol apotex | Cilostazol stada | Cilozek | Claudienne | Claudine | Noclaud | Pladizol;
(DE) Germany: Cilostazol al | Cilostazol hexal | Cilostazol stada | Pladizol | Pletal;
(DO) Dominican Republic: Ceudal | Cilostal | Cilostal xr | Cilosvitae | Citazol | Licuagen | Pletazol | Policor | Sadoxol | Xiltos 100;
(EC) Ecuador: Aclusin | Artesol | Cilostal | Cilosvitae | Clauter;
(EE) Estonia: Cilozek;
(EG) Egypt: Cilobiogen | Cilomepatal | Cilostalon | Claudicat | Claudol | Cludalost | Coaguless | Infarca | Movigretal | Pletaal | Sedotazole | Sercprove | Stazola | Stazotrend;
(ES) Spain: Cilostazol cinfa | Cilostazol kern pharma | Cilostazol midas | Cilostazol mylan | Cilostazol normon | Cilostazol pensa | Cilostazol ratiopharm | Cilostazol sandoz | Cilostazol stada genericos | Cilostazol tarbis | Cilostazol teva | Cilostazol vir | Cilostazol zentiva | Ekistol;
(GB) United Kingdom: Pletal;
(GR) Greece: Cilos | Cilostazol/adamed | Cilostazol/galenica | Claudiasil | Inclaud;
(HK) Hong Kong: Pletaal;
(HU) Hungary: Antaclast | Cilopeda | Cilostazol hspt | Cilozek | Noclaud;
(ID) Indonesia: Aggravan | Agrezol | Alista | Antiplat | Citaz | Fibrozol | Ilos | Naletal | Pletaal | Qital | Stazol;
(IE) Ireland: Pletal;
(IN) India: Cilesta | Cilodoc | Cilokem | Cilotab | Cletus | Clotazole | Cutaz | Pencil | Pletolog | Pletoz | Preclaud | Silosta | Stiloz | Vascilol | Zilast;
(IT) Italy: Albaten | Boiser | Cilostazolo Mylan | Cilostazolo sandoz | Fripass | Pletal;
(JP) Japan: Aitant | Cilosinamin | Cilosmerck | Cilostate | Cilostazol jg | Ecbarl | Ejennu | Fantezole | Fantezole alfresa | Flenied | Gront | Hordazol sanken | Hordazol y.taisho | Kortrythm | Opetarl | Platemeel | Plestazol | Plestazol chemipha | Pletaal | Pletmol | Prelazine | Ranomin | Rotazona | Rotazona choseido;
(KE) Kenya: Stiloz;
(KR) Korea, Republic of: Ahngook cilostazol | Alvogen cilostazol | Celetal | Celetal sr | Cilazol | Cilbesta | Cilbesta SR | Cilenta sr | Cilental | Cilental cr | Ciletal | Ciletal sr | Cilo k sr | Cilo m | Cilo v | Cilobell | Cilodil sr | Ciloen | Cilof | Cilogen | Cilontas | Ciloretal sr | Cilos | Cilos xr | Cilosta m | Cilosta m sr | Cilosta sr | Cilostal | Cilostan | Cilostin | Cilosto | Cilosto sr | Cilota | Cilotal | Cilotan | Cilotan sr | Cilotazole | Cilotec sr | Cilotel | Cilotel sr | Cilothera | Cilotin sr | Ciloto | Cilover sr | Cilozen | Cilsta | Ciltazol | Cilvesta sr | Citazol | Citazol sr | Daewoong cilostazol | Daewoong cilostazol sr | Hanlim cilostazol | Hucilo | Husilo sr | J letal cr | Jcilo cr | Kb stazol | Kbstazol | Kbstazol sr | Lantazol | Losazol | Losazol cr | Lostal | Lostal xr | Lotasil | Lotazol | Lozence | Newletal | Newta | Nocles | Plecilo sr | Pletaal | Plezol sr | Precilo sr | Prestazol | Preta | Preta sr | Pretol | Prostal | Prostal sr | Rostal | S cilo | S cilo SR | Samsung cilostazol | Samsung cilostazol SR | Smizol | Stazol | Tarocil | Unistal | Unistal sr | Unitazol | Uretazol sr;
(LB) Lebanon: Pletoz;
(LT) Lithuania: Dilsatan | Pletal | Sollazon;
(LV) Latvia: Dilsatan | Sollazon;
(MX) Mexico: Caudaline | Clauter | Joustox | Raamtol;
(MY) Malaysia: Cilosol | Pletaal;
(NO) Norway: Pletal;
(PE) Peru: Cilostal | Cilosvitae | Clauter | Pletaal;
(PH) Philippines: Ciletin | Cilostan cr | Clazol | Closcizol | Clostelo | Pencil | Platecil | Pletaal | Pletaxol | Stiloz | Thromzol | Trombocil | Vaxol | Zatsol;
(PK) Pakistan: Cilosta | Cilovas | Kladica | Labista | Lostaz | Pletaal | Walk Aid;
(PL) Poland: Cilostazol LEK AM | Cilostop | Cilozek | Decilosal | Noclaud | Pletal | Stepcil;
(PR) Puerto Rico: Pletal;
(PT) Portugal: Cilostazol ferrer;
(PY) Paraguay: Cilostazol quimfa | Ciltaz | Seclodin;
(RO) Romania: Cilostazol galenica | Dilvas | Noclaud | Pladizol | Velyn;
(RU) Russian Federation: Aducil | Pletax | Pletazol;
(SA) Saudi Arabia: Fancata;
(SE) Sweden: Cilostazol 2care4 | Cilostazol ebb | Cilostazol eql pharma | Pletal;
(SK) Slovakia: Cilostazol stada | Cilozek | Claudine;
(TH) Thailand: Cilosol | Citazol | Cylozza | Pletaal;
(TR) Turkey: Silnorm;
(TW) Taiwan: Cistazol | Loata | Pletaal | Pleya | Tilor;
(UA) Ukraine: Claudiex | Plestazol | Pletol;
(UY) Uruguay: Cilozol | Policor | Sadoxol | Vasogard;
(VE) Venezuela, Bolivarian Republic of: Cilostal | Hatial;
(VN) Viet Nam: Crybotas | Pletaz

Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
Bramer SL, Forbes WP. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol. Clin Pharmacokinet. 1999;37(suppl 2):25-32. [PubMed 10702884]
Cilostazol [prescribing information]. Columbus, OH: Slate Run Pharmaceuticals LLC; July 2020.
Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Ferraris VA, Saha SP, Oestreich JH, et al, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” Ann Thorac Surg, 2012, 94(5):1761-81. [PubMed 23098967]
Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6-46. [PubMed 26714677]
Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313-e1410. doi:10.1161/CIR.0000000000001251 [PubMed 38743805]
Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth Analg. 2011;112(2):292-318. doi:10.1213/ANE.0b013e318203f38d [PubMed 21212258]
Hirsch AT, Haskal ZJ, Hertzer NR, et al, “ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease),” Circulation , 2006, 113(11):e463-654. Available at http://www.acc.org/clinical/guidelines/pad/index.pdf [PubMed 16549646]
Ishii H, Kumada Y, Toriyama T, et al. Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients. Clin Ther. 2010;32(1):24-33. doi:10.1016/j.clinthera.2010.01.007 [PubMed 20171408]
Kim JS, Lee KS, Kim YI, Tamai Y, Nakahata R, Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci. 2004;11(6):600-602. [PubMed 15261228]
Mallikaarjun S, Forbes WP, Bramer SL. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. Clin Pharmacokinet. 1999;37(suppl 2):33-40. doi:10.2165/00003088-199937002-00004 [PubMed 10702885]
Pletal (cilostazol) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2017.
Refer to manufacturer’s labeling.
Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
Wilhite DB, Comerota AJ, Schmieder FA, Throm RC, Gaughan JP, Rao AK. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38(4):710-713. [PubMed 14560218]

Topic 8872 Version 373.0

خرید پکیج

Cilostazol: Drug information